Abiopharma

New Form EFFECT - Celularity Inc Filed: 2026-01-07 AccNo: 9999999995-26-000103 Size: 1 KB

New Form EFFECT - PRECISION BIOSCIENCES INC Filed: 2026-01-07 AccNo: 9999999995-26-000100 Size: 1 KB

Aclarion Provides 2025 Update and 2026 Corporate Outlook

Pathenbot, a Subsidiary of CN Energy (NASDAQ: CNEY), Receives LeaderXport × BossHub Innovation Award at CES 2026

Final approval of ANDA #ANDA #213514 for OLOPATADINE HYDROCHLORIDE. Decision date: 01/06/2026

Final approval of ANDA #ANDA #213476 for ROCURONIUM BROMIDE. Decision date: 01/06/2026

Final approval of ANDA #ANDA #219167 for BORTEZOMIB. Decision date: 01/06/2026

General Announcement: DEALINGS IN LISTED SECURITIES (CHAPTER 14 OF LISTING REQUIREMENTS): DEALINGS OUTSIDE CLOSED PERIOD

Salarius Pharmaceuticals Inc. (SLRX) was removed from the list of traded instruments on NASDAQ exchange

FibroGen Inc (FGEN) was removed from the list of traded instruments on NASDAQ exchange

Cidara Therapeutics Inc. (CDTX) was removed from the list of traded instruments on NASDAQ exchange

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: FibroGen, Inc - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: FibroGen, Inc - Common Stock. New value: FibroGen, Inc - Common Stock.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Salarius Pharmaceuticals, Inc. - Common Stock. New value: Salarius Pharmaceuticals, Inc. - Common Stock.